Close Menu

In a paper published online in advance in the PNAS Early Edition this week, a team led by investigators at Harvard Medical School shows that, in a mouse model of pancreatic neuorendocrine cancer, administration of the endogenous angiogenesis inhibitors endostatin, thrombospondin-1, and tumstatin peptides, "as well as deletion of their genes, reveal neoplastic stage-specific effects on angiogenesis, tumor progression, and survival, correlating with endothelial expression of their receptors." Further, the team reports its finding that the deletion of tumstatin and thrombospondin-1 in

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.